What is Eucalyptus?
Founded in 2019 and headquartered in New South Wales, Eucalyptus functions as a sophisticated private-pay healthcare platform. The company addresses the complexities of the Australian two-payer medical system by offering a seamless, consumer-centric alternative that bypasses traditional administrative friction. By integrating clinical expertise with digital accessibility, Eucalyptus has established itself as a leader in the telehealth sector, providing patients with efficient, high-quality care options that align with contemporary expectations for on-demand medical services. Its business model is designed to scale rapidly, leveraging digital infrastructure to expand its reach across diverse therapeutic areas.
How much funding has Eucalyptus raised?
Eucalyptus has raised a total of $112.3M across 3 funding rounds:
Series A
$30M
Series B
$22.3M
Series C
$60M
Series A (2021): $30M with participation from Blackbird
Series B (2021): $22.3M led by W23, NewView Capital, AirTree Ventures, and Blackbird Ventures
Series C (2022): $60M supported by BOND
Key Investors in Eucalyptus
Blackbird Ventures
Blackbird is an Australian venture capital firm that exists to supercharge the company's most ambitious founders by partnering with them at the very beginning of their journey.
AirTree Ventures
Airtree is an early-stage venture capital firm that supports Australian and New Zealand founders in building iconic technology companies through a portfolio of over 125 companies.
NewView Capital
NewView Capital is a venture growth firm that specializes in investing in high-potential enterprise software and fintech companies through primary and secondary investments.
What's next for Eucalyptus?
With the infusion of capital from its latest financing round, Eucalyptus is well-positioned to accelerate its operational expansion and deepen its technological capabilities. The company is expected to focus on scaling its service offerings, potentially entering new therapeutic verticals and enhancing its proprietary patient management platform. As it moves beyond its initial growth phase, the strategic deployment of these funds will likely prioritize market penetration and the solidification of its brand as the premier digital health destination in the ANZ region. Investors remain optimistic that the firm will continue to disrupt traditional healthcare delivery models, setting new benchmarks for efficiency and patient outcomes in the private-pay sector.
See full Eucalyptus company page
